KEY BUSINESS HIGHLIGHTS Phase 2a clinical trial for Cholesterol Efflux Mediator VAR 200 in patients with diabetic kidney disease expected to begin Q1-2025.New Obesity, Metabolic & Inflammatory Disease ...
Skye Bioscience, Inc. (Nasdaq: SKYE) ("Skye"), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic health ...
A key player in the market, Apnea Sciences Corporation contributes to innovative solutions that address the diverse causes of snoring. Its commitment to research and development positions it as a ...
Report Ocean has published a new report on the Narcolepsy Therapeutics Market, delivering an extensive analysis of key factors such as market restraints, drivers, and opportunities. The report offers ...